Back to top
more

Verastem (VSTM)

(Delayed Data from NSDQ)

$6.89 USD

6.89
994,951

+0.07 (1.03%)

Updated Aug 21, 2026 04:00 PM ET

After-Market: $6.90 +0.01 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Verastem (VSTM) delivered earnings and revenue surprises of +54.12% and -86.36%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Gossamer Bio (GOSS) delivered earnings and revenue surprises of +5.56% and +155.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline

by Zacks Equity Research

Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moumi Mondal headshot

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?

by Moumi Mondal

TEM's Genomics revenues soar 89% on oncology test gains and Ambry Genetics' boost. New assays could fuel more growth.

Zacks Equity Research

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

by Zacks Equity Research

Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.

Zacks Equity Research

Verastem Oncology to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of any marketed drugs, investors are set to focus on VSTM's pipeline updates when it reports first-quarter 2025 earnings.

Kinjel Shah headshot

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

by Kinjel Shah

If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.

Zacks Equity Research

Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 100.9% in Verastem (VSTM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

by Zacks Equity Research

The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.

Zacks Equity Research

Verastem (VSTM) Begins Dosing in Solid Tumors Study in China

by Zacks Equity Research

Verastem (VSTM) doses the first patient in a phase I/II study conducted by GenFleet Therapeutics, evaluating KRAS G12D inhibitor, GFH375/VS-7375 in solid tumors. Shares rise.